Chi‐Lu Chiang

657 total citations
56 papers, 415 citations indexed

About

Chi‐Lu Chiang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Chi‐Lu Chiang has authored 56 papers receiving a total of 415 indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 43 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Chi‐Lu Chiang's work include Lung Cancer Treatments and Mutations (36 papers), Lung Cancer Research Studies (31 papers) and Brain Metastases and Treatment (12 papers). Chi‐Lu Chiang is often cited by papers focused on Lung Cancer Treatments and Mutations (36 papers), Lung Cancer Research Studies (31 papers) and Brain Metastases and Treatment (12 papers). Chi‐Lu Chiang collaborates with scholars based in Taiwan, United States and Japan. Chi‐Lu Chiang's co-authors include Chao‐Hua Chiu, Yung‐Hung Luo, Yuh‐Min Chen, Chun‐Ming Tsai, Teh‐Ying Chou, Tsu‐Hui Shiao, Yi‐Chen Yeh, Yuh-Min Chen, Jin‐Yuan Shih and Cheng‐Chia Lee and has published in prestigious journals such as PLoS ONE, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Chi‐Lu Chiang

47 papers receiving 408 citations

Peers

Chi‐Lu Chiang
J.D. Schoenfeld United States
Andreas Domen Belgium
Junwen Huang China
Ethan Srinivasan United States
Erika Gedvilaite United States
Carmen Mota Reyes Germany
J.P. Bahary Canada
Jonathan P. Giurintano United States
Masayuki Komatsu Japan
J.D. Schoenfeld United States
Chi‐Lu Chiang
Citations per year, relative to Chi‐Lu Chiang Chi‐Lu Chiang (= 1×) peers J.D. Schoenfeld

Countries citing papers authored by Chi‐Lu Chiang

Since Specialization
Citations

This map shows the geographic impact of Chi‐Lu Chiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chi‐Lu Chiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chi‐Lu Chiang more than expected).

Fields of papers citing papers by Chi‐Lu Chiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chi‐Lu Chiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chi‐Lu Chiang. The network helps show where Chi‐Lu Chiang may publish in the future.

Co-authorship network of co-authors of Chi‐Lu Chiang

This figure shows the co-authorship network connecting the top 25 collaborators of Chi‐Lu Chiang. A scholar is included among the top collaborators of Chi‐Lu Chiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chi‐Lu Chiang. Chi‐Lu Chiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chiang, Chi‐Lu, Ross A. Soo, Tony Mok, et al.. (2025). A comparison of clinical guidelines, treatment characteristics and outcomes in small cell lung cancer between East Asia and Europe/North America. Frontiers in Oncology. 15. 1646608–1646608.
2.
Lin, Chun‐Fu, Chi‐Lu Chiang, Huai‐Che Yang, et al.. (2025). BBB-penetrant tyrosine kinase inhibitor plus intracranial radiotherapy vs BBB-penetrant TKI alone in Asians with EGFR-mutated lung adenocarcinoma and brain metastases. Journal of the Chinese Medical Association. 88(12). 933–940.
3.
Luo, Yung‐Hung, et al.. (2024). Immune signatures of patients with advanced non-small-cell lung cancer for efficacy prediction after immunotherapy. Therapeutic Advances in Medical Oncology. 16. 12729682–12729682. 1 indexed citations
4.
Tseng, Yen-Han, Chih‐Feng Chian, Chi‐Lu Chiang, et al.. (2024). Immune killer cells treatment for previously treated stage IV NSCLC patients. Scientific Reports. 14(1). 19374–19374.
5.
Wu, Yuan‐Hung, Heng‐Sheng Chao, Chi‐Lu Chiang, et al.. (2023). Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cell‐derived organoids. Thoracic Cancer. 14(25). 2591–2600. 4 indexed citations
6.
Kuo, Chih‐Hsi S., Po‐Lan Su, Yu‐Feng Wei, et al.. (2023). T790M detection rate after first-line combination therapy with bevacizumab and EGFR-TKIs in advanced NSCLC (TERRA Study). PubMed Central. 3 indexed citations
7.
8.
Che, Ting-Fang, Chao‐Hua Chiu, Yu‐Chung Wu, et al.. (2023). Proliferative ability of circulating tumor cells is a prognostic factor in Early-Stage lung adenocarcinoma. Lung Cancer. 178. 198–205. 4 indexed citations
9.
Ho, Hsiang‐Ling, Yuqiu Jiang, Chi‐Lu Chiang, et al.. (2022). Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer. PLoS ONE. 17(4). e0267362–e0267362. 8 indexed citations
10.
Luo, Yung‐Hung, Kung‐Hao Liang, Chi‐Lu Chiang, et al.. (2022). State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan. International Journal of Molecular Sciences. 23(13). 7037–7037. 7 indexed citations
11.
Chiang, Chi‐Lu, et al.. (2022). Recent Advances in the Diagnosis and Management of Multiple Primary Lung Cancer. Cancers. 14(1). 242–242. 16 indexed citations
12.
Ho, Hsiang‐Ling, Fangyu Wang, Chi‐Lu Chiang, et al.. (2022). Dynamic Assessment of Tissue and Plasma EGFR-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs. International Journal of Molecular Sciences. 23(19). 11353–11353. 9 indexed citations
13.
Chiang, Chi‐Lu, Ching‐Jen Chen, Huai‐Che Yang, et al.. (2022). EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases. Journal of Neuro-Oncology. 159(3). 675–684.
14.
Chen, Yu‐Chi, Huai‐Che Yang, Chi‐Lu Chiang, et al.. (2022). Natural history of lung squamous cell brain metastases in patients treated with radiosurgery: a thirty-year experience at a tertiary medical center. Journal of Neuro-Oncology. 161(1). 135–146.
15.
Lin, Yen‐Ting, Chi‐Lu Chiang, Jen‐Yu Hung, et al.. (2021). Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non–small-cell lung cancer: a multicenter study using targeted next-generation sequencing. European Journal of Cancer. 156. 1–11. 25 indexed citations
16.
Chiang, Chi‐Lu, Cheng‐Chia Lee, Chia‐Hung Wu, et al.. (2021). Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis. Targeted Oncology. 16(2). 207–214. 13 indexed citations
17.
18.
Chiang, Chi‐Lu, Yi‐Chen Yeh, & Chao‐Hua Chiu. (2019). EP1.14-35 Squamous Cell Carcinoma Transformation After Acquired Resistance to Osimertinib. Journal of Thoracic Oncology. 14(10). S1045–S1045.
19.
Su, Wei‐Juin, Chi‐Lu Chiang, Jia‐Yih Feng, et al.. (2017). The predictive value of the interferon-γ release assay for chemotherapy responses in patients with advanced non-small-cell lung cancer. Lung Cancer. 115. 64–70. 6 indexed citations
20.
Chiang, Chi‐Lu, Chun‐Ming Tsai, Teh‐Ying Chou, et al.. (2012). Erlotinib in patients with advanced lung squamous cell carcinoma. Cancer Chemotherapy and Pharmacology. 71(1). 203–208. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J.D. Schoenfeld Breakdown of academic impact, for papers by Andreas Domen Breakdown of academic impact, for papers by Junwen Huang Breakdown of academic impact, for papers by Ethan Srinivasan Breakdown of academic impact, for papers by Erika Gedvilaite Breakdown of academic impact, for papers by Carmen Mota Reyes Breakdown of academic impact, for papers by J.P. Bahary Breakdown of academic impact, for papers by Jonathan P. Giurintano Breakdown of academic impact, for papers by Masayuki Komatsu
Rankless by CCL
2026